BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 34246118)

  • 1. Safety and efficacy of adjunctive lacosamide in Chinese and Japanese adults with epilepsy and focal seizures: A long-term, open-label extension of a randomized, controlled trial.
    Inoue Y; Liao W; Wang X; Du X; Tennigkeit F; Sasamoto H; Osakabe T; Hoshii N; Yuen N; Hong Z
    Epilepsy Res; 2021 Oct; 176():106705. PubMed ID: 34246118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial.
    Ben-Menachem E; Baulac M; Hong SB; Cleveland JM; Reichel C; Schulz AL; Wagener G; Brandt C
    Epilepsy Res; 2021 Feb; 170():106526. PubMed ID: 33461041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial.
    Arnold S; Laloyaux C; Schulz AL; Elmoufti S; Yates S; Fakhoury T
    Epilepsy Res; 2020 Oct; 166():106404. PubMed ID: 32731118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.
    Husain A; Chung S; Faught E; Isojarvi J; McShea C; Doty P
    Epilepsia; 2012 Mar; 53(3):521-8. PubMed ID: 22372628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: A randomized, double-blind, placebo-controlled study.
    Hong Z; Inoue Y; Liao W; Meng H; Wang X; Wang W; Zhou L; Zhang L; Du X; Tennigkeit F;
    Epilepsy Res; 2016 Nov; 127():267-275. PubMed ID: 27669155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retention, efficacy, tolerability, and quality of life during long-term adjunctive brivaracetam treatment by number of lifetime antiseizure medications: A post hoc analysis of phase 3 trials in adults with focal seizures.
    Brandt C; Dimova S; Elmoufti S; Laloyaux C; Nondonfaz X; Klein P
    Epilepsy Behav; 2023 Jan; 138():108967. PubMed ID: 36435010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and tolerability of lacosamide monotherapy in patients with epilepsy: Results from a multicenter, open-label trial.
    Ben-Menachem E; Dominguez J; Szász J; Beller C; Howerton C; Jensen L; McClung C; Roebling R; Steiniger-Brach B
    Epilepsia Open; 2021 Sep; 6(3):618-623. PubMed ID: 34265173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, multicenter, noninterventional study in Taiwan to evaluate the safety and tolerability of lacosamide as adjunctive therapy for epilepsy in clinical practice.
    Wu T; Chuang YC; Huang HC; Lim SN; Hsieh PF; Lee WT; Cheng MY; Tsai MH; Jou SB; Chang CW; Hsieh HY; Du X; Hellot S; McClung C; Hung C
    Epilepsy Behav; 2020 Dec; 113():107464. PubMed ID: 33152580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years.
    Rosenfeld W; Fountain NB; Kaubrys G; Ben-Menachem E; McShea C; Isojarvi J; Doty P;
    Epilepsy Behav; 2014 Dec; 41():164-70. PubMed ID: 25461210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: A phase III randomized, double-blind, placebo-controlled trial.
    Inoue Y; Tiamkao S; Zhou D; Cabral-Lim L; Lim KS; Lim SH; Tsai JJ; Moseley B; Wang L; Sun W; Hayakawa Y; Sasamoto H; Sano T; McClung C; Bass A
    Epilepsia Open; 2024 Jun; 9(3):1007-1020. PubMed ID: 38576178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy.
    Ben-Menachem E; Grebe HP; Terada K; Jensen L; Li T; De Backer M; Steiniger-Brach B; Gasalla T; Brock M; Biton V
    Epilepsia; 2019 Dec; 60(12):2437-2447. PubMed ID: 31755090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
    Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
    Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial.
    O'Brien TJ; Borghs S; He QJ; Schulz AL; Yates S; Biton V
    Epilepsia; 2020 Apr; 61(4):636-646. PubMed ID: 32221987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
    Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: Results from a multicenter, open-label trial.
    Vossler DG; Wechsler RT; Williams P; Byrnes W; Therriault S;
    Epilepsia; 2016 Oct; 57(10):1625-1633. PubMed ID: 27528101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
    Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
    Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs.
    Sake JK; Hebert D; Isojärvi J; Doty P; De Backer M; Davies K; Eggert-Formella A; Zackheim J
    CNS Drugs; 2010 Dec; 24(12):1055-68. PubMed ID: 21090839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of short-term infusions of intravenous lacosamide in pediatric patients with epilepsy: An open-label, phase 2/3 trial.
    Farkas MK; Beller C; Bozorg A; McClung C; Roebling R; Yates T; Yuen N; Makedonska I
    Epilepsia Open; 2023 Mar; 8(1):146-153. PubMed ID: 36529709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis.
    Moseley BD; Dimova S; Elmoufti S; Laloyaux C; Asadi-Pooya AA
    Epilepsy Res; 2021 Oct; 176():106694. PubMed ID: 34218211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies.
    Weiping L; Dong Z; Zhen H; Patten A; Dash A; Malhotra M
    CNS Neurosci Ther; 2021 Mar; 27(3):330-340. PubMed ID: 33340263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.